The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs

Advanced Drug Delivery Reviews

Volumn 40, Issue 1-2, 1999, Pages 75-87

  Nagayasu, A ^a   Uchiyama, K ^b   Kiwada, H ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b Faculty of Pharmaceutical Sciences   (Japan)

Author keywords

Antitumor activity; Blood circulation; Drug delivery; Drug release; Pharmacokinetics; Toxicity; Tumor accumulation; Vesicle size

Indexed keywords

HEMODYNAMICS; ONCOLOGY; PHARMACOKINETICS; TOXICITY;

LIPOSOMES;

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; ERYTHROMYCIN; LIPOSOME; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CAPILLARY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; ELECTRON SPIN RESONANCE; HUMAN; IN VIVO STUDY; INTERSTITIUM; LEUKEMIA; MELANOMA; MONONUCLEAR PHAGOCYTE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SARCOMA; TUMOR VASCULARIZATION;

EID: 0032866761     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00041-1     Document Type: Article

References (86)

1. Zee-Cheng R.K.-Y., Cheng C.C. Delivery of anticancer drugs. Methods Find. Exp. Clin. Pharmacol. 11:1989;439-529.
2. Poznansky M.J., Juliano R.L. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol. Rev. 36:1984;277-336.
3. Poste G., Kirsh R., Bugelski P. Liposomes as a drug delivery system in cancer therapy. Sunkara P.S. Novel Approaches to Cancer Chemotherapy. 1984;165-230 Academic Press, New York.
4. Abra R.M., Hunt C.A. Liposome disposition in vivo III: dose and vesicle-size effects. Biochim. Biophys. Acta. 666:1981;493-503.
5. Allen T.M., Everest J.M. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J. Pharmacol. Exp. Ther. 226:1983;539-544.
6. Harashima H., Kiwada H. Liposomal targeting and drug delivery: kinetic consideration. Adv. Drug Deliv. Rev. 19:1996;425-444.
7. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.-D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA. 88:1991;11460-11464.
8. Huang S.K., Lee K.-D., Friend D.S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52:1992;5135-5143.
9. Huang S.K., Martin F.J., Gilbert J., Vogel J., Papahadjopoulos D., Friend D.S. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am. J. Pathol. 143:1993;10-14.
10. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res. 54:1994;3352-3356.
11. Unezaki S., Maruyama K., Hosoda J., Nagase I., Koyanagi Y., Nakata M., Ishida O., Iwatsuru M., Tsuchiya S. Direct measurement of extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int. J. Pharm. 144:1996;11-17.
12. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55:1995;3752-3756.
13. Liu D., Mori A., Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim. Biophys. Acta. 1104:1992;95-101.
14. Uchiyama K., Nagayasu A., Yamagiwa Y., Nishida T., Harashima H., Kiwada H. Effects of the size and fluidity of liposomes on their accumulation in tumors: a presumption of their interaction with tumors. Int. J. Pharm. 121:1995;195-203.
15. Oku N., Tokudome Y., Tsukada H., Okada S. Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography. Biochim. Biophys. Acta. 1238:1995;86-90.
16. Mayer L.D., Tai L.C.L., Ko D.S.C., Masin D., Ginsberg R.S., Cullis P.R., Bally M.B. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 49:1989;5922-5930.
17. Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52:1992;891-896.
18. Nagayasu A., Shimooka T., Kinouchi Y., Uchiyama K., Takeichi Y., Kiwada H. Effects of fluidity and vesicle size on antitumor activity and myelosuppressive activity of liposomes loaded with daunorubicin. Biol. Pharm. Bull. 17:1994;935-939.
19. Zou Y., Ling Y.-H., Reddy S., Priebe W., Perez-Soler R. Effects of vesicle size and lipid composition in the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes. Int. J. Cancer. 61:1995;666-671.
20. Bally M.B., Nayar R., Masin D., Cullis P.R., Mayer L.D. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother. Pharmacol. 27:1990;13-19.
21. Patel H.M. Serum opsonins and liposomes: Their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;39-90.
22. Devine D.V., Marjan M.J. The role of immunoproteins in the survival of liposomes in the circulation. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;105-131.
23. Richards R.L., Habbersett R.C., Scher I., Janoff A.S., Schieren H.P., Mayer L.D., Cullis P.R., Alving P.R. Influence of vesicle size on complement-dependent immune damage to liposomes. Biochim. Biophys. Acta. 855:1986;223-230.
24. Devine D.V., Wong K., Serrano K., Chonn A., Cullis P.R. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim. Biophys. Acta. 1191:1994;43-51.
25. Harashima H., Hiraiwa T., Ochi Y., Kiwada H. Size-dependent liposome degradation in blood: in vitro/in vivo correlation by kinetic modeling. J. Drug. Target. 3:1995;253-261.
26. Harashima H., Huong T.M., Ishida I., Manabe Y., Matsuo H., Kiwada H. Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats. Pharm. Res. 13:1996;1704-1709.
27. Szebeni J. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carrier Syst. 15:1998;57-88.
28. Senior J.H. Fate and behavior of liposomes in vivo; a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3:1987;123-193.
29. Senior J.H., Greoriadis G. Stability of small unilamellar in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci. 30:1982;2123-2136.
30. Senior J., Crawley J.C.W., Gregoriadis G. Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim. Biophys. Acta. 839:1985;1-8.
31. Allen T.M., Hansen C., Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta. 981:1989;27-35.
32. Juriano R.L., Stamp D. The effect of particle size and charge on the clearance of liposomes and liposome encapsulated drugs. Biochem. Biophys. Res. Commun. 63:1975;651-658.
33. Souhami R., Patel H.M., Ryman B.E. The effect of reticuloendothelial blockade on the blood clearance and tissue distribution of liposomes. Biochim. Biophys. Acta. 674:1981;354-371.
34. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo: relation to circulation lifetimes. J. Biol. Chem. 267:1992;18759-18765.
35. Proffitt R.T., Williams L.E., Presant C.A., Tin G.W., Uliana J.A., Gamble R.C., Baldeschwieler J.D. Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. Science. 220:1983;502-505.
36. Allen T.M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223:1987;42-46.
37. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA. 85:1988;6949-6953.
38. Gabizon A., Price D.C., Huberty J., Bresalier R.S., Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 50:1990;6371-6378.
39. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:1990;235-237.
40. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066:1991;29-36.
41. Woodle M.C., Matthay K.K., Newman M.S., Hidayat J.E., Cullis P.R., Redemann C., Martin F.J., Papahadjopoulos D. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim. Biophys. Acta. 1105:1992;193-200.
42. Namba Y., Sakakibara T., Masada M., Ito F., Oku N. 1-O-Palmityl-D-glucuronate endows liposomes with long half-life in vivo. Chem. Lett. 1989:1989;2145-2148.
43. Yamauchi H., Yano T., Kato T., Tanaka I., Nakabayashi S., Higashi K., Miyoshi S., Yamada H. Effects of sialic acid derivative on long circulation time and tumor concentration of liposomes. Int. J. Pharm. 113:1995;141-148.
44. Allen T.M., Hansen C. Pharmacokinetics of Stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta. 1068:1991;133-141.
45. Oku N., Namba Y., Okada S. Tumor accumulation of novel RES-avoiding liposomes. Biochim. Biophys. Acta. 1126:1992;255-260.
46. Litzinger D.C., Buiting A.M.J., van Rooijen N., Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta. 1190:1994;99-107.
47. Gabizon A., Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta. 1103:1992;94-100.
48. Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta. 1062:1991;142-148.
49. Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta. 1062:1991;77-82.
50. Maruyama K., Yuda T., Okamoto A., Kojima S., Suginaka A., Iwatsuru M. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim. Biophys. Acta. 1128:1992;44-49.
51. Oku N. Long-circulating liposomes. Crit. Rev. Ther. Drug Carrier Syst. 11:1994;231-270.
52. Oku N. In vivo trafficking of long-circulating liposomes in tumor-bearing mice determined by positron emission tomography. Biopharm. Drug Dispos. 17:1996;435-441.
53. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:1987;559-593.
54. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6:1989;193-210.
55. Nagayasu A., Uchiyama K., Nishida T., Yamagiwa Y., Kawai Y., Kiwada H. Is control of distribution of liposomes between tumors and bone marrow possible? Biochim. Biophys. Acta. 1278:1996;29-34.
56. Parr M.J., Masin A., Cullis P., Bally M.B. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J. Pharmacol. Exp. Ther. 280:1997;1319-1327.
57. Takakura Y., Takagi A., Hashida M., Sezaki H. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4:1987;293-300.
58. Tabata Y., Murakami Y., Ikada Y. Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. J. Control. Release. 50:1998;123-133.
59. Weissig V., Whiteman K.R., Torchilin V.P. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm. Res. 15:1998;1552-1556.
60. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributed to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53:1993;3765-3770.
61. Hirano A., Matsui T. Vascular structures in brain tumors. Hum. Pathol. 6:1975;611-621.
62. Warren B.A. The ultrastructure of the microcirculation at the advancing edge of Walker 256 carcinoma. Microvasc. Res. 2:1970;443-453.
63. Wisse E., DeZanger R.B., Charels K., Van Der Smissen P., McCuskey R.S. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology. 5:1985;683-692.
64. Daemen T., Velonova M., Regts J., de Jager M., Kalicharan R., Donga J., van der Want J.J.L., Scherphof G.L. Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat. Hepatology. 26:1997;416-423.
65. Hobbs S.K., Monsky W.L., Yuan F., Riberts W.G., Driffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenviroment. Proc. Natl. Acad. Sci. USA. 95:1998;4607-4612.
66. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:1989;570-576.
67. Horowitz A.T., Barenholz Y., Gabizon A.A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim. Biophys. Acta. 1109:1992;203-209.
68. Allen T.M., Ryan J.L., Papahadjopoulos D. Gangliosides reduce leakage of aqueous-space markers from liposomes in the presence of human plasma. Biochim. Biophys. Acta. 818:1985;205-210.
69. Blume G., Cevc G. Liposomes for sustained drug release in vivo. Biochim. Biophys. Acta. 1029:1990;91-97.
70. Hernández-Caselles T., Villalaín J., Gómez-Fernández J.C. Influence of liposome charge and composition on their interaction with human blood serum proteins. Mol. Cell. Biochem. 120:1993;119-126.
71. Kirby C., Clarke J., Greoriadis G. Effect of cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 186:1980;591-598.
72. Nagayasu A., Shimooka T., Kiwada H. Effects of vesicle size on in vivo release of daunorubicin from hydrogenated egg phosphatidylcholine-based liposomes into blood circulation. Biol. Pharm. Bull. 18:1995;1020-1023.
73. Storm G., Nässader U.K., Roerdink F.H., Steerenberg P.A., de Jong W.H., Crommelin D.J.A. Studies on the mode of action of doxorubicin-liposomes. Lopez-Berestein G., Fidler I.J. Liposomes in The Therapy of Infectious Diseases and Cancer. 1989;105-116 Alan T. Liss, New York.
74. Gabizon A., Shiota R., Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 81:1989;1484-1488.
75. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54:1994;987-992.
76. Unezaki S., Maruyama K., Ishida O., Suginaka A., Hosoda J., Iwatsuru M. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol). Int. J. Pharm. 126:1995;41-48.
77. Forssen E.A., Malé-Brune R., Adler-Moore J.P., Lee A.J.A., Schmidt P.G., Krasieva T.B., Shimizu S., Tromberg B. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 56:1996;2066-2075.
78. Forssen E.A., Coulter D.M., Proffitt R.T. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 52:1992;3255-3261.
79. Oku N., Doi K., Namba Y., Okada S. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int. J. Cancer. 58:1994;415-419.
80. Gabizon A., Chemla M., Tzemach D., Horowitz A.T., Goren D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J. Drug Target. 3:1996;391-398.
81. Urakami Y., Harashima H., Iida S., Nagayasu A., Kiwada H. Kinetic study on the optimization of tumor delivery of antitumor agents by liposomes: simulation study based on the physiological modeling [in Japanese]. Drug Deliv. Syst. 12:1997;403-408.
82. Mayer L.D., Bally M.B., Loughrey H., Masin D., Cullis P.R. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 50:1990;575-579.
83. Gabizon A., Amselem S., Goren D., Cohen R., Druckmann S., Fromer I., Chisin R., Peretz T., Sulkes A., Barenholz Y. Preclinical and clinical experience with a doxorubicin-liposome preparation. J. Liposome Res. 1:1990;491-502.
84. Forssen E.A., Ross M.E. DaunoXome treatment of solid tumors: preclinical and clinical investigations. J. Liposome Res. 4:1994;481-512.
85. Working P.K., Newman M.S., Huang S.K., Mayhew E., Vaage J., Lasic D.D. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil). J. Liposome Res. 4:1994;667-687.
86. Skubitz K.M., Skubitz A.P.N. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil™). Anti-Cancer Drugs. 9:1998;45-50.